Search
Gastric intrinsic factor
go.drugbank.com/drugs/DB09349Approvedon in the small intestine. … Intrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later
Mixtures: EnLyte Extra-LNDesipramine
go.drugbank.com/drugs/DB01151ApprovedIn depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexSynonyms: DMI, N-(3-methylaminopropyl)iminobibenzylUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab … allowing for administration in a one-hour infusion twice-a-year following the starting dose.
Antigen peptide transporter 1
go.drugbank.com/bio_entities/BE0003109TransporterHumansIn complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091
Synonyms: Peptide transporter involved in antigen processing 1Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsIloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigational[A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Categories: Dopamine D2 Receptor AntagonistsAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … Ancestim is a non-glycosylated recombinant methionyl human stem cell factor.
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigationalLanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.
Categories: Drugs Used in Hereditary AngioedemaThioridazine
go.drugbank.com/drugs/DB00679ApprovedWithdrawnA phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. … Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Synonyms: 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazineCategories: Dopamine D2 Receptor Antagonists